Now, researchers reporting in ACS Infectious Diseases have revealed that infections with 2 various HCoVs dont produce antibodies that efficiently cross-react with SARS-CoV-2. Sebastien Fiedler, Tuomas Knowles and coworkers wanted to compare the strength and concentration of antibodies versus HCoVs and SARS-CoV-2 in the sera of nine recuperated COVID-19 clients and in three pre-pandemic sera.
The outcomes suggest that there is no substantial cross-reactivity of antibodies against common HCoVs and SARS-CoV-2, and therefore, no anticipated negative or protective results of antibody cross-reactivity for these coronaviruses, the scientists say.
Transmission electron micrograph of SARS-CoV-2 virus particles, separated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID
Now, researchers reporting in ACS Infectious Diseases have actually shown that infections with 2 various HCoVs do not produce antibodies that successfully cross-react with SARS-CoV-2. Previous infection with HCoVs is not likely to secure versus COVID-19 or worsen a SARS-CoV-2 infection through antibody-dependent improvement (ADE), the researchers say.
On the other hand, if the antibodies versus HCoVs recognize SARS-CoV-2, however not highly sufficient to produce an immune action, they could cause ADE. Sebastien Fiedler, Tuomas Knowles and colleagues wanted to compare the strength and concentration of antibodies versus HCoVs and SARS-CoV-2 in the sera of 9 recuperated COVID-19 patients and in three pre-pandemic sera.
They found that all 9 recovered COVID-19 sera samples contained moderate quantities of antibodies with high affinity to the SARS-CoV-2 spike protein. In contrast, none of the pre-pandemic sera consisted of high-affinity antibodies for SARS-CoV-2. The outcomes suggest that there is no significant cross-reactivity of antibodies against typical HCoVs and SARS-CoV-2, and for that reason, no anticipated protective or unfavorable results of antibody cross-reactivity for these coronaviruses, the researchers say.
Referral: “Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2” 30 March 2022, ACS Infectious Diseases.DOI: 10.1021/ acsinfecdis.1 c00486.
The authors acknowledge financing from the University of Zurich, the University Hospital of Zurich, the NOMIS Foundation, the European Research Council, the National Institute for Health Research, the P.I. Terasaki Scholar program, and the Biotechnology and Biological Sciences Research Council.
